Viro - viro - Ravimiamet

sopharma ad - amlodipiin - tablett - 10mg 20tk; 10mg 98tk; 10mg 56tk; 10mg 28tk; 10mg 300tk; 10mg 60tk; 10mg 14tk; 10mg 21tk

Viro - viro - Ravimiamet

pharmaceutical works polpharma s.a. - esomeprasool - süste-/infusioonilahuse pulber - 40mg 10viaal

Viro - viro - Ravimiamet

pharmaswiss ceska republika s.r.o. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk

Viro - viro - Ravimiamet

pharmaswiss ceska republika s.r.o. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 100mg 1tk

Viro - viro - Ravimiamet

sopharma ad - askorbiinhape - süste-/infusioonilahus - 100mg 1ml 2ml 10tk; 100mg 1ml 5ml 10tk

Euroopan unioni - viro - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Viro - viro - Ravimiamet

pharmaswiss ceska republika s.r.o. - takroliimus - kõvakapsel - 1mg 30tk; 1mg 90tk; 1mg 20tk; 1mg 60tk; 1mg 100tk

Viro - viro - Ravimiamet

pharmaswiss ceska republika s.r.o. - takroliimus - kõvakapsel - 0,5mg 30tk; 0,5mg 50tk; 0,5mg 60tk; 0,5mg 20tk; 0,5mg 100tk

Viro - viro - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 8mg 28tk; 8mg 14tk; 8mg 56tk

Viro - viro - Ravimiamet

pharmaceutical works polpharma s.a. - kandesartaan - tablett - 4mg 14tk; 4mg 28tk